A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
← catalyst calendarNCT06970743 · readout in 1,199 d
Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
153actual
Sites
56
Countries
China, Taiwan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-29 | actual | When the study began enrolling |
| Primary completion | 2029-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
- Drug: BGB-16673
- Drug: Bendamustine
- Drug: Rituximab
- Drug: Methylprednisolone
- Drug: Chlorambucil
- Drug: Obinutuzumab
Primary outcome
what the primary-completion date above is the date OFProgression-Free Survival (PFS) by IRC
measured Approximately 23 Months
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed